湖南南新制药股份有限公司关于以集中竞价交易方式回购公司股份的进展公告

Group 1 - The company has approved a share repurchase plan with a budget between RMB 10 million and RMB 20 million, aiming to buy back its A-shares at a price not exceeding RMB 9.53 per share within 12 months [2][3] - As of July 31, 2025, the company has repurchased a total of 265,516 shares, representing 0.10% of its total share capital of 274,400,000 shares, with a total expenditure of RMB 1,967,393.92 [3][4] - The highest and lowest prices for the repurchased shares were RMB 7.86 and RMB 7.02 per share, respectively [3] Group 2 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [5]